Table 3 Measurements of Figs. 6 and 7
From: Are radiologists ready to evaluate true response to immunotherapy?
Target lesions | RECIST | irRC | irRECIST | iRECIST |
|---|---|---|---|---|
Baseline: right kidney: 21 × 10 mm, lymph node: nontarget (< 15 mm in short axis), right parietal lobe: non -target (< 10 mm in long axis) |  |  |  |  |
First control: Right kidney: 23 × 12 mm, lymph node: non-target, right parietal lobe: 13.6 × 12 mm | SD | Not for chemotherapy treatment response evaluation | Not for chemotherapy treatment response evaluation | Not for chemotherapy treatment response evaluation |
Second control: Right kidney: 55 × 38 mm, right parietal lobe 20.6 × 15 mm | PD | PD (> %25 increase in total tumor burden) | PD (> %20 increase in total tumor burden) | iUPD Need to be confirmed at 4–8 weeks |
Target new lesions: Right liver lobe:38 × 32 mm, lymph nodes:25 × 18 mm and 28 × 39 mm pleural nodules:12 × 4 mm and 11 × 5 mm |  |  |  |  |
Non-target new lesions: Pleural effusion and < 10 mm pleural nodules |  |  |  |  |